QUÉBEC CITY, Nov. 1, 2012 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the "Company") today announced that its Director of
Preclinical Development, Babette Aicher, PhD, will be making a poster
presentation on preclinical results for disorazol Z cytotoxic
conjugates, such as AEZS-125, in ovarian cancer, at the upcoming 24th EORTC-NCI-AACR (ENA) Symposium on "Molecular Targets and Cancer
Therapeutics", which will be held November 6-9, 2012 in Dublin,
Ireland. The study is funded through a grant from the German Ministry
of Education and Research.
"Highly Potent Cytotoxic Conjugates of Disorazol Z Linked to a
LHRH-Receptor Targeting Peptide, such as AEZS-125, Interfere with Cell
Cycle Progression in Human Cancer Cell Lines and Suppress Tumor Growth
in a LHRH Receptor Positive Ovarian Cancer Xenograft Model ", B. Aicher, T. Schuster, L. Blumenstein, P. Schmidt, H. Irschik, R.
Jansen, R. Mueller, E. Guenther, M. Teifel.
Monoclonal Antibodies and Targeted Toxins/Nuclides
Thursday, November 8, 2012, from 12 noon to 2:15 pm (local time)
Convention Centre Dublin
About Disorazol Z cytotoxic conjugate, AEZS-125
AEZS-125 is a disorazol Z (AEZS-137) cytotoxic conjugate linked to a
Luteinizing Hormone-Releasing Hormone (LHRH)-receptor targeting
peptide. Disorazol Z is a novel natural compound isolated from
myxobacterium Soranglium cellulosum with outstanding cytotoxic
activity. Disorazol Z is a macrocyclic polyketide which is available
via fermentation in high yield and purity. Besides tubulin binding,
disorazol Z has pro-apoptotic properties and arrested cancer cells in
G2 stage of the cell cycle at subnanomolar concentrations. Disorazol Z
is an ideal partner for the formation of cytotoxic conjugates with
peptides and proteins to selectively target cancer cells.
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug development
company currently investigating treatments for various unmet medical
needs. The Company's pipeline encompasses compounds at all stages of
development, from drug discovery through to marketed products. For more
information please visit www.aezsinc.com.
SOURCE: AETERNA ZENTARIS INC.
For further information:
Ginette Beaudet Vallières
Investor Relations Coordinator
(418) 652-8525 ext. 265
Director of Communications
(418) 652-8525 ext. 406